Clario

Pennsylvania-based Clario is a clinical trial technology solution provider that offers a variety of software solutions to help researchers expedite clinical trial progress. The company offers software solutions with regard to clinical trial management, cardiac safety, medical imaging, respiratory solutions, trial enablement, and decentralized trials. The company additionally offers consulting services for sponsors and researchers to identify potential improvements to be more patient-centric, maintain data control, and create flexible trial environments. Clario additionally carries out research on behalf of organizations through its partnership with Cogstate, called “Cogstate Research.”

Clario operates on a B2B basis, providing its platforms to research organizations and biopharmaceutical companies. The company also provides its consulting services to sponsors and research on a fee-per-service model.

In March 2023, the company introduced its Federated Identity Management (FIM) system to enhance the security and user experience for its clinical trial platform. The system offers a secure and user-friendly authentication method, allowing users to use the same credentials across different systems and organizations. It helps to manage access to online resources and services, enforces security policies across Clario's Clinical Platform, and ensures compliance with data protection regulations like HIPAA and GDPR.

In April 2024, Clario acquired AI-powered software company ArtiQ for an undisclosed sum. The acquisition was carried out to expand Clario's AI capabilities in its portfolio of respiratory solutions, while additionally enhancing the company's ability to leverage and develop AI across its service lines.  

In June 2024, according to a Bloomberg report, Clario confidentially filed for an initial public offering with the US Securities and Exchange Commission and was targeting a valuation of more than USD 10 billion.

Key customers and partnerships

Most recently, in October 2024, Clario partnered with PathAI, an AI-powered digital pathology solutions company, to improve gastrointestinal (GI) clinical trials. The partnership aimed to offer a single-vendor solution that combines Clario's advanced imaging solutions like endoscopy with PathAI's AI-powered histopathology services. The integrated approach aimed to streamline endoscopic and histopathology end points, improving efficiency in global GI studies.

In August 2024, Clario partnered with Mobilise-D consortium to integrate Digital Mobility Outcomes (DMOs) into clinical trials. The collaboration integrated Mobilise-D's validated algorithms into Clario's Opal wearable sensor system, enabling real-world mobility assessments for patients. The integration allowed for more objective, reliable, and accurate measurements of human movement compared to conventional clinical scales, particularly benefiting neuroscience studies, where mobility insights outside clinical settings are crucial. Clario implemented these algorithms in a study with multiple sclerosis patients to establish the technical equivalence of its Opal precision motion device. The partnership aimed to enhance clinical outcomes by combining mobility performance data from wearable sensors with electronic clinical outcome assessment (eCOA).

In August 2023, Clario expanded its partnership with personal electrocardiogram (ECG) technology provider AliveCor to enable ECG readings to be collected from trial participant’s homes. Through the expanded collaboration, Clario trial participants will be able to collect medical-grade six-lead ECG readings via AliveCor’s devices and app, KardiaRx.

Clario joined public-private partnership CancerX in June 2023 to act as an accelerator to boost innovation in developing treatments for cancer. Through the partnership, Clario joined Digital Medicine Society (DiMe), Moffitt Cancer Center, the Office for the National Coordinator for Health Information Technology (ONC), and the Office of the Assistant Secretary for Health (OASH) to accelerate the pace of development for cancer therapeutics in the US through its knowledge and 50 years’ worth experience in cancer-related and other clinical trials.

In addition, Clario partnered with Strados in March 2023 to provide respiratory technology for clinical trials. Through the partnership, Clario gained access to Strados’ FDA-approved RESP Biosensor respiratory monitoring system, which uploaded patient readings to Clario’s platform while charging during clinical trials. During the same month, Clario also partnered with ArtiQ to incorporate AI for clinical trial collection for spirometry. Through the partnership, ArtiQ’s AI will review spirometry data collected on Clario’s platform for clinical trials.

In May 2022, the company expanded its partnership with Cogstate to improve data collection and quality during clinical trials. Through the partnership, Clario’s eCOA Multimedia technology platforms will collect audio, photo, and patient/clinician data, while Cogstate will provide global clinical network and deep therapeutic expertise in neurodegenerative diseases. This partnership expands on previous agreements, where Clario’s eCOA platform was combined with Cogstate’s digital cognitive assessments to streamline clinical trial outcomes.